Annual EBITDA
$309.69 M
+$42.77 M+16.02%
31 December 2023
Summary:
BioMarin Pharmaceutical annual earnings before interest, taxes, depreciation & amortization is currently $309.69 million, with the most recent change of +$42.77 million (+16.02%) on 31 December 2023. During the last 3 years, it has risen by +$226.03 million (+270.20%). BMRN annual EBITDA is now at all-time high.BMRN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$156.41 M
-$5.76 M-3.55%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly earnings before interest, taxes, depreciation & amortization is currently $156.41 million, with the most recent change of -$5.76 million (-3.55%) on 30 September 2024. Over the past year, it has increased by +$85.28 million (+119.89%). BMRN quarterly EBITDA is now -5.40% below its all-time high of $165.34 million, reached on 31 March 2022.BMRN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$506.72 M
+$85.28 M+20.24%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM earnings before interest, taxes, depreciation & amortization is currently $506.72 million, with the most recent change of +$85.28 million (+20.24%) on 30 September 2024. Over the past year, it has increased by +$238.70 million (+89.06%). BMRN TTM EBITDA is now at all-time high.BMRN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.0% | +119.9% | +89.1% |
| 3 y3 years | +270.2% | +1112.3% | +643.1% |
| 5 y5 years | +9289.6% | +259.6% | +10000.0% |
BMRN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +552.9% | -5.4% | +519.0% | at high | +968.3% |
| 5 y | 5 years | at high | +9289.6% | -5.4% | +519.0% | at high | >+9999.0% |
| alltime | all time | at high | +144.4% | -5.4% | +128.7% | at high | +172.6% |
BioMarin Pharmaceutical EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $156.41 M(-3.6%) | $506.72 M(+20.2%) |
| June 2024 | - | $162.17 M(+18.9%) | $421.44 M(+17.3%) |
| Mar 2024 | - | $136.44 M(+164.0%) | $359.25 M(+16.0%) |
| Dec 2023 | $309.69 M(+16.0%) | $51.69 M(-27.3%) | $309.69 M(+15.5%) |
| Sept 2023 | - | $71.13 M(-28.9%) | $268.03 M(+19.4%) |
| June 2023 | - | $99.98 M(+15.1%) | $224.47 M(+19.1%) |
| Mar 2023 | - | $86.88 M(+766.4%) | $188.47 M(-29.4%) |
| Dec 2022 | $266.92 M(+462.7%) | $10.03 M(-63.6%) | $266.92 M(+21.6%) |
| Sept 2022 | - | $27.58 M(-56.9%) | $219.56 M(+24.4%) |
| June 2022 | - | $63.98 M(-61.3%) | $176.53 M(+11.9%) |
| Mar 2022 | - | $165.34 M(-542.8%) | $157.75 M(+232.6%) |
| Dec 2021 | $47.43 M(-43.3%) | -$37.34 M(+141.6%) | $47.43 M(-30.4%) |
| Sept 2021 | - | -$15.45 M(-134.2%) | $68.19 M(+16.3%) |
| June 2021 | - | $45.20 M(-17.8%) | $58.65 M(+1397.4%) |
| Mar 2021 | - | $55.02 M(-431.8%) | $3.92 M(-95.3%) |
| Dec 2020 | $83.66 M(+162.1%) | -$16.58 M(-33.6%) | $83.13 M(-31.1%) |
| Sept 2020 | - | -$24.98 M(+162.1%) | $120.62 M(-36.2%) |
| June 2020 | - | -$9.53 M(-107.1%) | $189.11 M(-0.2%) |
| Mar 2020 | - | $134.23 M(+542.0%) | $189.44 M(+503.1%) |
| Dec 2019 | $31.92 M(-1047.1%) | $20.91 M(-51.9%) | $31.41 M(+1076.0%) |
| Sept 2019 | - | $43.50 M(-573.2%) | $2.67 M(-111.7%) |
| June 2019 | - | -$9.19 M(-61.4%) | -$22.77 M(+115.6%) |
| Mar 2019 | - | -$23.80 M(+204.0%) | -$10.56 M(+213.4%) |
| Dec 2018 | -$3.37 M(-103.7%) | -$7.83 M(-143.4%) | -$3.37 M(-103.4%) |
| Sept 2018 | - | $18.05 M(+498.0%) | $98.57 M(+9.1%) |
| June 2018 | - | $3.02 M(-118.2%) | $90.34 M(+29.0%) |
| Mar 2018 | - | -$16.61 M(-117.7%) | $70.02 M(-23.0%) |
| Dec 2017 | $90.97 M(-113.0%) | $94.11 M(+857.9%) | $90.97 M(-237.1%) |
| Sept 2017 | - | $9.82 M(-156.8%) | -$66.36 M(-36.4%) |
| June 2017 | - | -$17.31 M(-498.9%) | -$104.42 M(-83.5%) |
| Mar 2017 | - | $4.34 M(-106.9%) | -$632.28 M(-9.4%) |
| Dec 2016 | -$698.01 M(+861.6%) | -$63.22 M(+123.9%) | -$698.01 M(+34.1%) |
| Sept 2016 | - | -$28.24 M(-94.8%) | -$520.43 M(-7.4%) |
| June 2016 | - | -$545.17 M(+788.2%) | -$561.97 M(+667.5%) |
| Mar 2016 | - | -$61.38 M(-153.7%) | -$73.22 M(+9.1%) |
| Dec 2015 | -$72.59 M(+58.9%) | $114.36 M(-263.9%) | -$67.09 M(-70.9%) |
| Sept 2015 | - | -$69.78 M(+23.7%) | -$230.15 M(+70.9%) |
| June 2015 | - | -$56.42 M(+2.1%) | -$134.63 M(+60.5%) |
| Mar 2015 | - | -$55.25 M(+13.5%) | -$83.88 M(+95.1%) |
| Dec 2014 | -$45.69 M(-65.2%) | -$48.70 M(-289.2%) | -$42.98 M(+23.0%) |
| Sept 2014 | - | $25.74 M(-554.3%) | -$34.94 M(-64.8%) |
| June 2014 | - | -$5.67 M(-60.5%) | -$99.22 M(-1.2%) |
| Mar 2014 | - | -$14.36 M(-64.7%) | -$100.44 M(-14.7%) |
| Dec 2013 | -$131.12 M(+94.9%) | -$40.65 M(+5.5%) | -$117.75 M(+3.9%) |
| Sept 2013 | - | -$38.54 M(+459.2%) | -$113.32 M(+55.2%) |
| June 2013 | - | -$6.89 M(-78.2%) | -$73.04 M(-14.5%) |
| Mar 2013 | - | -$31.66 M(-12.6%) | -$85.47 M(+31.0%) |
| Dec 2012 | -$67.26 M(>+9900.0%) | -$36.23 M(-2178.4%) | -$65.26 M(+56.5%) |
| Sept 2012 | - | $1.74 M(-109.0%) | -$41.70 M(-19.3%) |
| June 2012 | - | -$19.32 M(+68.6%) | -$51.65 M(+126.8%) |
| Mar 2012 | - | -$11.46 M(-9.5%) | -$22.77 M(>+9900.0%) |
| Dec 2011 | -$172.00 K | -$12.66 M(+54.1%) | -$171.00 K(-104.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$8.21 M(-185.9%) | $3.93 M(-78.6%) |
| June 2011 | - | $9.56 M(-14.2%) | $18.35 M(-1.2%) |
| Mar 2011 | - | $11.14 M(-230.1%) | $18.58 M(+8.9%) |
| Dec 2010 | $17.07 M(-52.1%) | -$8.56 M(-237.9%) | $17.07 M(-54.0%) |
| Sept 2010 | - | $6.21 M(-36.6%) | $37.08 M(-19.7%) |
| June 2010 | - | $9.79 M(+1.7%) | $46.18 M(-5.4%) |
| Mar 2010 | - | $9.63 M(-16.0%) | $48.80 M(+37.0%) |
| Dec 2009 | $35.63 M(-47.2%) | $11.46 M(-25.1%) | $35.63 M(-40.2%) |
| Sept 2009 | - | $15.31 M(+23.4%) | $59.56 M(+2.2%) |
| June 2009 | - | $12.41 M(-450.0%) | $58.28 M(+2.4%) |
| Mar 2009 | - | -$3.54 M(-110.0%) | $56.92 M(-8.7%) |
| Dec 2008 | $67.43 M(-227.4%) | $35.40 M(+152.4%) | $62.38 M(+244.0%) |
| Sept 2008 | - | $14.02 M(+26.9%) | $18.14 M(-249.8%) |
| June 2008 | - | $11.05 M(+478.3%) | -$12.10 M(-66.1%) |
| Mar 2008 | - | $1.91 M(-121.6%) | -$35.66 M(-33.1%) |
| Dec 2007 | -$52.92 M(+255.6%) | -$8.85 M(-45.4%) | -$53.27 M(-3.0%) |
| Sept 2007 | - | -$16.22 M(+29.6%) | -$54.89 M(+38.2%) |
| June 2007 | - | -$12.51 M(-20.3%) | -$39.70 M(+60.4%) |
| Mar 2007 | - | -$15.70 M(+49.9%) | -$24.76 M(+74.5%) |
| Dec 2006 | -$14.88 M(-72.7%) | -$10.47 M(+916.5%) | -$14.18 M(+0.7%) |
| Sept 2006 | - | -$1.03 M(-142.2%) | -$14.09 M(-40.8%) |
| June 2006 | - | $2.44 M(-147.6%) | -$23.81 M(-44.1%) |
| Mar 2006 | - | -$5.12 M(-50.6%) | -$42.62 M(-21.8%) |
| Dec 2005 | -$54.47 M(-59.5%) | -$10.38 M(-3.4%) | -$54.47 M(-55.3%) |
| Sept 2005 | - | -$10.74 M(-34.4%) | -$121.89 M(-10.1%) |
| June 2005 | - | -$16.37 M(-3.6%) | -$135.61 M(+0.9%) |
| Mar 2005 | - | -$16.97 M(-78.2%) | -$134.46 M(-0.1%) |
| Dec 2004 | -$134.63 M(+102.9%) | -$77.80 M(+218.0%) | -$134.63 M(+69.2%) |
| Sept 2004 | - | -$24.47 M(+60.7%) | -$79.56 M(+9.2%) |
| June 2004 | - | -$15.23 M(-11.2%) | -$72.84 M(+12.0%) |
| Mar 2004 | - | -$17.14 M(-24.6%) | -$65.05 M(-2.0%) |
| Dec 2003 | -$66.36 M(+12.2%) | -$22.73 M(+28.1%) | -$66.36 M(-2.4%) |
| Sept 2003 | - | -$17.74 M(+138.5%) | -$68.00 M(+8.1%) |
| June 2003 | - | -$7.44 M(-59.7%) | -$62.93 M(-5.1%) |
| Mar 2003 | - | -$18.46 M(-24.3%) | -$66.29 M(+12.1%) |
| Dec 2002 | -$59.12 M(+45.5%) | -$24.37 M(+92.4%) | -$59.12 M(+13.4%) |
| Sept 2002 | - | -$12.66 M(+17.3%) | -$52.15 M(+11.1%) |
| June 2002 | - | -$10.80 M(-4.4%) | -$46.95 M(+6.4%) |
| Mar 2002 | - | -$11.29 M(-35.1%) | -$44.13 M(+12.1%) |
| Dec 2001 | -$40.63 M(+35.7%) | -$17.40 M(+132.9%) | -$39.38 M(+14.9%) |
| Sept 2001 | - | -$7.47 M(-6.3%) | -$34.28 M(+3.4%) |
| June 2001 | - | -$7.97 M(+21.8%) | -$33.15 M(+8.1%) |
| Mar 2001 | - | -$6.54 M(-46.8%) | -$30.68 M(+2.4%) |
| Dec 2000 | -$29.94 M(+46.9%) | -$12.30 M(+94.1%) | -$29.94 M(+25.7%) |
| Sept 2000 | - | -$6.34 M(+15.5%) | -$23.82 M(+2.3%) |
| June 2000 | - | -$5.49 M(-5.5%) | -$23.28 M(+2.7%) |
| Mar 2000 | - | -$5.81 M(-6.1%) | -$22.68 M(+10.8%) |
| Dec 1999 | -$20.38 M(+68.5%) | -$6.18 M(+6.6%) | -$20.47 M(+43.3%) |
| Sept 1999 | - | -$5.80 M(+18.6%) | -$14.28 M(+68.4%) |
| June 1999 | - | -$4.89 M(+36.0%) | -$8.48 M(+136.0%) |
| Mar 1999 | - | -$3.59 M | -$3.59 M |
| Dec 1998 | -$12.10 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual EBITDA year-on-year change?
- What is BioMarin Pharmaceutical quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly EBITDA year-on-year change?
- What is BioMarin Pharmaceutical TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM EBITDA year-on-year change?
What is BioMarin Pharmaceutical annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of BMRN is $309.69 M
What is the all time high annual EBITDA for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual earnings before interest, taxes, depreciation & amortization is $309.69 M
What is BioMarin Pharmaceutical annual EBITDA year-on-year change?
Over the past year, BMRN annual earnings before interest, taxes, depreciation & amortization has changed by +$42.77 M (+16.02%)
What is BioMarin Pharmaceutical quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of BMRN is $156.41 M
What is the all time high quarterly EBITDA for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly earnings before interest, taxes, depreciation & amortization is $165.34 M
What is BioMarin Pharmaceutical quarterly EBITDA year-on-year change?
Over the past year, BMRN quarterly earnings before interest, taxes, depreciation & amortization has changed by +$85.28 M (+119.89%)
What is BioMarin Pharmaceutical TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of BMRN is $506.72 M
What is the all time high TTM EBITDA for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM earnings before interest, taxes, depreciation & amortization is $506.72 M
What is BioMarin Pharmaceutical TTM EBITDA year-on-year change?
Over the past year, BMRN TTM earnings before interest, taxes, depreciation & amortization has changed by +$238.70 M (+89.06%)